| abstract |
The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease comprising thioridazine (Thioridazine). The composition comprising thiridazine of the present invention reduces steatosis, inflammation or ballooning in non-alcoholic fatty liver-induced liver tissue, reduces the level of fibrosis of inflammation caused by non-alcoholic fatty liver, and prevents non-alcoholic fatty liver disease. By reducing the increased liver weight, it may be provided for the use of preventing or treating metabolic liver diseases, including non-alcoholic fatty liver disease. |